The UK arm of US-based pharmaceutical company Eli Lilly, which
produces the anti-depressant Prozac, has drawn up a shortlist for its
public affairs account.
GJW, APCO Associates, Bruce Naughton Wade and Grandfield are all in the
running for the account, which is rumoured to be worth between pounds
40,000 and pounds 50,000 in fees.
The review of Lilly’s public affairs activity follows the arrival of
Stephen Whitehead as director of corporate affairs in February.
Whitehead was previously director of external affairs at GrandMet.
Whitehead said the public affairs brief would include raising Lilly’s
profile in Government, monitoring the Government’s plans for the future
of the NHS and healthcare policy, and focus on alliance building.
’Considering the size of the company we don’t have much of a profile at
the moment,’ he said.
Lilly’s best-known product Prozac has a one third share of the
anti-depressant market in the UK. The company also produces the
schizophrenia treatment Zyprexa and the insulin product Humalog. It
claims to be the UK’s seventh largest drugs company.
Public affairs was previously handled by Edelman, which declined to
repitch for the account. Edelman, Cohn and Wolfe and Fleishman-Hillard
all handle product work for Lilly in the UK.